Post-transplant cyclophosphamide. A treatment strategy following hematopoietic cell transplantation to reduce the occurrence of complications, such as graft-versus-host-disease and graft rejection, particularly in patients whose donors are not fully HLA-matched. Purpura: Large areas of bruising.
« Back to Glossary IndexNews
Related News
Katherine (middle) with 2023's recipient Ana Tabar (left) and FCF CEO Isis Sroka (right) The De Los Santos family first experienced the complexities of Fanconi anemia as they endured the devastating loss of their daughter, Gracie, who passed away from...
We recognize the holiday season can be difficult amidst grief, whether caused by the loss of a loved one, anticipatory grief, or living losses. Join Lori Krause for this workshop where participants will acknowledge and validate their emotions, then discuss...
The Fanconi Cancer Foundation (FCF) is excited to announce that Dr. Isis Sroka has been named CEO effective August 1, 2024. She succeeds Mark Quinlan who served as Executive Director since 2017 and recently announced his departure. Quinlan will continue in an advisory role with FCF through a transition period.